Nurix Therapeutics (NASDAQ:NRIX) & Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Critical Comparison

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.

Volatility and Risk

Valion Bio, Inc. Common Stock has a beta of 1.8, meaning that its share price is 80% more volatile than the S&P 500. Comparatively, Nurix Therapeutics has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.

Profitability

This table compares Valion Bio, Inc. Common Stock and Nurix Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Valion Bio, Inc. Common Stock	N/A	-193.17%	-67.10%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Insider & Institutional Ownership

4.3% of Valion Bio, Inc. Common Stock shares are owned by institutional investors. 2.5% of Valion Bio, Inc. Common Stock shares are owned by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Valion Bio, Inc. Common Stock and Nurix Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Valion Bio, Inc. Common Stock	1	0	0	0	1.00
Nurix Therapeutics	1	1	13	0	2.80

Nurix Therapeutics has a consensus price target of $34.21, suggesting a potential upside of 50.52%. Given Nurix Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than Valion Bio, Inc. Common Stock.

Earnings & Valuation

This table compares Valion Bio, Inc. Common Stock and Nurix Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Valion Bio, Inc. Common Stock	$780,000.00	2.50	-$8.88 million	($159.25)	-0.01
Nurix Therapeutics	$83.98 million	28.09	-$264.46 million	($3.45)	-6.59

Valion Bio, Inc. Common Stock has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Valion Bio, Inc. Common Stock, indicating that it is currently the more affordable of the two stocks.

Summary

Nurix Therapeutics beats Valion Bio, Inc. Common Stock on 10 of the 14 factors compared between the two stocks.

About Valion Bio, Inc. Common Stock

Tivic Health Systems Inc. operates as a health tech company, focuses on developing and commercializing bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for the treatment of sinus and nasal inflammation. The company sells its products on direct-to-consumer channel through its own websites; and platforms, such as Amazon.com and Walmart.com, as well as to U.S. online retailers, such as BestBuy and FSAStore and through distributors. Tivic Health Systems, Inc. was incorporated in 2016 and is headquartered in Hayward, California.

About Nurix Therapeutics

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.